Healight
Treatment Technology by Cedars-Sinai and Aytu Biosciences, Inc.
UVA Light Device to Treat COVID-19
Trial Registration: ClinicalTrials.gov #NCT04572399
The proposal is to use Healight in the treatment of COVID-19.
Dr. Mark Pimentel is the lead of the Healight team.
The research team of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai has been developing the patent-pending Healight platform since 2016 and has produced a growing body of scientific evidence demonstrating pre-clinical safety and effectiveness of the technology as an antiviral and antibacterial treatment.
The Healight technology employs proprietary methods of administering intermittent ultraviolet (UV) A light via a novel endotracheal medical device. Pre-clinical findings indicate the technology’s significant impact on eradicating a wide range of viruses and bacteria, inclusive of coronavirus.
The data have been the basis of discussions with the FDA for a near-term path to enable human use for the potential treatment of coronavirus in intubated patients in the intensive care unit (ICU).
Beyond the initial pursuit of a coronavirus ICU indication, additional data suggest broader clinical applications for the technology across a range of viral and bacterial pathogens. This includes bacteria implicated in ventilator associated pneumonia (VAP).
“Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells,” stated Dr. Pimentel of Cedars-Sinai.
Ali Rezaie, MD, one of the inventors of this technology states, “Our lab at Cedars-Sinai has extensively studied the effects of this unique technology on bacteria and viruses. Based on our findings we believe this therapeutic approach has the potential to significantly impact the high morbidity and mortality of coronavirus-infected patients and patients infected with other respiratory pathogens. We are looking forward to partnering with Aytu BioScience to move this technology forward for the benefit of patients all over the world.”
The company believes the Healight platform technology has the potential to positively impact outcomes for critically ill patients infected with coronavirus and severe respiratory infections. The company licensed exclusive worldwide rights to the technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. Patents have been filed by Cedars-Sinai Department of Technology Transfer, and Aytu BioScience will manage all aspects of intellectual property prosecution and filing globally. Aytu BioScience expects to partner the product outside the U.S.
“We are honored to be partnering with Cedars-Sinai as we believe the Healight therapeutic platform has the potential to help many patients during this coronavirus pandemic and beyond,” said Josh Disbrow, Chairman and CEO of Aytu BioScience.
The Company is engaging with the research team at Cedars-Sinai and the FDA to determine an expedited regulatory process to potentially enable near-term use of the technology initially as a coronavirus intervention for critically ill intubated patients.
Disbrow continued, “This first-in-class technology has the potential to be a game changer for clinicians treating patients infected with coronavirus and other respiratory conditions, and our team is working tirelessly alongside the Cedars-Sinai team to determine the safety and effectiveness of this device in humans.”
- Can you get pulled over in NC for having bright...on January 27, 2023 at 12:31 am
Bright headlights can be useful while driving on certain roads or dark highways, but they can also be a nuisance to other drivers. Last month, a North Carolina resident posted about their ...
- Blaming senior drivers for blinding headlights is...on January 24, 2023 at 10:46 pm
Q: A letter writer blamed older folks for bright headlights on cars, saying that they need these lights because of failing eyesight. That’s absurd! Seniors don’t design cars being built.
- Aytu BioPharma Regains Nasdaq Minimum Bid Price...on January 24, 2023 at 9:06 pm
ENGLEWOOD, CO / ACCESSWIRE / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric ...
- Aytu BioPharma, Inc.: Aytu BioPharma Regains...on January 24, 2023 at 9:03 pm
ENGLEWOOD, CO / ACCESSWIRE / January 25, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric ...
- Aytu BioPharma to Present at Lytham Partners...on January 24, 2023 at 8:59 pm
ENGLEWOOD, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused ...
- Aytu BioPharma to Present at Lytham Partners...on January 24, 2023 at 11:27 am
ENGLEWOOD, CO / ACCESSWIRE / January 24, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric ...
- Meguiar’s recalls headlight sealanton January 24, 2023 at 8:00 am
Photo source: CPSC Meguiar’s of Irvine, Calif., is recalling about 140,000 containers of heavy duty headlight sealant. The headlight sealant contains low-viscosity hydrocarbons which must be in ...
- Aytu BioPharma to Present at Lytham Partners...on January 23, 2023 at 9:12 pm
The Company's webcast presentation will be available for viewing at 9:00 am ET on Tuesday, January 31, 2023, on the Company's website at https://irdirect.net/AYTU or ...
https://cedars.app.box.com/s/0lqm2slw1vlyt4j5em70xregfro4592t